Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson chief Executive Officer annual total compensation ($) ($)
DEF 14A Proxy Statement (CEO Pay Ratio)
Latest, FY2025
32,784,511
Period ended Dec 28, 2025
Change on a year earlier
+34.8%
24,327,495 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Chief Executive Officer annual total compensation ($) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 32,784,511 | +34.8% | Proxy Statement (DEF 14A) (jnj-20260309.htm, filed 2026-03-11) ↗ |
| FY2024 | Dec 29, 2024 | 24,327,495 | -14.4% | Proxy Statement (DEF 14A) (jnj-20250311.htm, filed 2025-03-12) ↗ |
| FY2023 | Dec 31, 2023 | 28,422,037 | +116.6% | Proxy Statement (DEF 14A) (jnj-20240311.htm, filed 2024-03-13) ↗ |
| FY2022 | Jan 1, 2023 | 13,121,860 | -51.0% | Proxy Statement (DEF 14A) (jnj-20230313.htm, filed 2023-03-15) ↗ |
| FY2021 | Jan 2, 2022 | 26,757,015 | -9.6% | Proxy Statement (DEF 14A) (a2022jnjproxy.htm, filed 2022-03-16) ↗ |
| FY2020 | Jan 3, 2021 | 29,590,472 | +16.6% | Proxy Statement (DEF 14A) (jnjproxy2021.htm, filed 2021-03-10) ↗ |
| FY2019 | Dec 29, 2019 | 25,380,258 | – | Proxy Statement (DEF 14A) (jnjproxy2020.htm, filed 2020-03-11) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson Chief Executive Officer annual total compensation ($) ($), annual FY2019–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ceo_total_comp
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.